From PsychonautWiki
Jump to navigation Jump to search

This page has not been fully approved by the PsychonautWiki administrators.

It may contain incorrect information, particularly with respect to dosage, duration, subjective effects, toxicity and other risks. It may also not meet PW style and grammar standards.

Chemical Nomenclature
Common names Fluorexetamine, FXE
Substitutive name 3-F-2′-Oxo-PCE
Systematic name 2-(Ethylamino)-2-(3-fluorophenyl)cyclohexan-1-one
Class Membership
Psychoactive class Dissociative
Chemical class Arylcyclohexylamine
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.

Threshold 2.5 mg
Light 5 - 15 mg
Common 15 - 37.5 mg
Strong 37.5 - 75 mg
Heavy 75 mg +
Total 2 - 2.5 hours
After effects 4 - 8 hours

DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.


Fluorexetamine (3'-Fluoro-2-oxo-PCE, FXE) is a recreational designer drug from the arylcyclohexylamine family. According to anecdotal reports fluorexetamine produces dissociative and analgesic effects and is described to be slightly more stimulating than ketamine.

History and culture

It is a new designer drug that has been reportedly sold over the internet since around 2017. In April 2023 it was revealed by that all their previously analyzed samples of fluorexetamine actually contained 2'-Fluoro-2-oxo-PCE (2-FXE, also known as CanKet) rather than 3'-Fluoro-2-oxo PCE (3-FXE). This was confirmed by a newly available reference standard for 2-FXE. Similar misidentification may have occurred in other laboratories.


Fluorexetamine, or 2-(ethylamino)-2-(3-fluorophenyl)cyclohexan-1-one, is classed as an arylcyclohexylamine drug. Arylcyclohexylamine drugs are named for their structures which include a cyclohexane ring bound to an aromatic ring along with an amine group. Deschloroketamine contains a phenyl ring with a 3'-Flouro substitution bonded to a cyclohexane ring substituted with an oxo group (cyclohexanone) at R1. Bound to the adjacent alpha carbon (R2) of the cyclohexanone ring is an amino ethyl chain -NCH2CH3.


Due to the lack of research regarding the substance, all discussion regarding its pharmacology is purely based on its structure and subjective effect similarities to other arylcyclohexylamine dissociatives such as ketamine, PCE and methoxetamine (3-MeO-2'-Oxo-PCE). While no scientific studies have been conducted to verify this, structure-activity relationship analysis suggests that Fluorexetamine likely exhibits its observed effects principally as an NMDA receptor antagonist, although other neurotransmitter systems may be involved.

NMDA receptors (a subtype of receptors for glutamate, which are the principle excitatory neurotransmitters in the nervous system) allow for electrical signals to pass between nerve cells in the brain and spinal column; for the signals to pass, the receptor must be open. NMDA receptor antagonists have been shown to disrupt this signaling by blocking these receptors. This disconnection of information flow in the nervous system leads to loss of sensation (anesthesia), difficulty moving (motor discoordination), and eventually this substance's equivalent of the “K-hole.”

Subjective effects

Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.

It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.

Physical effects

Visual effects

Cognitive effects

Disconnective effects

Multi-sensory effects

Experience reports

There are currently 0 experience reports which describe the effects of this substance in our experience index.

Additional experience reports can be found here:

Toxicity and harm potential

Dangerous interactions

Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).

Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.

  • Alcohol - Both substances cause ataxia and bring a very high risk of vomiting and unconsciousness. If the user falls unconscious while under the influence there is a severe risk of vomit aspiration if they are not placed in the recovery position.
  • Amphetamines - May increase mania.
  • Cannabis - Cannabis majorly amplifies the sensory and cognitive effects. This interaction can also amplify the anxiety, confusion and delusion producing aspects of cannabis significantly. Those who choose to use this combination are advised to start off with only a fraction of their usual cannabis dose, and slow down the pace of their normal intake considerably.
  • Dissociatives - Both synergise.
  • Cocaine - May increase mania.
  • GHB / GBL - Both substances cause ataxia and bring a risk of vomiting and unconsciousness. If the user falls unconscious while under the influence there is a severe risk of vomit aspiration if they are not placed in the recovery position.
  • Opioids - Both substances bring a risk of vomiting and unconsciousness. If the user falls unconscious while under the influence there is a severe risk of vomit aspiration if they are not placed in the recovery position.
  • Tramadol - Tramadol lowers the seizure threshold. Both substances increase the risk of vomiting and unconsciousness.

External links


  1. Wallach J, Brandt SD (2018). "1,2-Diarylethylamine- and Ketamine-Based New Psychoactive Substances". New Psychoactive Substances. Handbook of Experimental Pharmacology. Vol. 252. pp. 305–352. doi:10.1007/164_2018_148. ISBN 978-3-030-10560-0. PMID 30196446.
  1. Erowid, DrugsData org /. " (was EcstasyData): Test Details : Result #15191 - White Crystals, 15191". & Retrieved 2023-12-02.